Option chain shows key data for IMAC Holdings's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for IMAC Holdings.

IMAC Holdings (OTC:BACK) Stock, Option Chain

IMAC Hldgs

IMAC Holdings Inc is engaged in providing services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. The Company has determined that it currently operates in a single segment, precision medicine in cancer treatment, located in a single geographic location, the United States.

WallStreet.Banks.Shutterstock

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

BACK

CNSP

DATS

MULN

MURA

TNON

US Stocks Mixed; Core &amp; Main Posts Downbeat Earnings

Wall Street subway sign

Earnings

BHAT

SLXN

SXTP

ZKIN

US Stocks Mixed; General Dynamics Earnings Top Views

F5's,Technology,Center,In,Silicon,Valley,,San,Jose,,Ca,,Usa

Pre-Market Outlook

Movers

ALRS

BNZI

CCEC

CGBS

CTRI

CULP

FFIE

FFIV

JYNT

LGCL

MANH

MLYS

Why F5 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

IMAC Holdings Inc

Backblaze Inc

Backstageplay Inc

Press Releases

IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors

IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology

IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1)

IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies

Stocks Under $2 to Watch in February 2025: TRIB, MODD, PNPN.V, BACK – More Inside!

Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response

Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay

Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

Comments

IMAC Holdings

IMAC Holdings (BACK) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell